Latest Distributions News

Page 19 of 447
Way2VAT is betting that its new Way2Invoice platform, Coupa distribution and Go-Global partnership can convert product momentum into recurring revenue, while a 15% cost reduction begins to address ongoing cash burn. Quarterly revenue was broadly flat at A$1.90 million, with A$3.05 million in cash and A$5.20 million of debt drawn at quarter end.
Victor Sage
Victor Sage
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026
Antilles Gold remains largely stalled in Cuba after its joint venture was designated a US Specially Designated National, with only site security continuing at Nueva Sabana. A conditional GEM deal could bring US$18 million and a path towards sanction relief, but the company ended September with just US$882,000 in cash.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Optiscan has moved its InForm and InVue medical-imaging devices into formal US FDA review after a quarter of intensive regulatory and clinical work. The milestone comes with $11.093 million in cash and a reported 3.5 quarters of funding at the latest operating burn rate.
Victor Sage
Victor Sage
30 Oct 2026
Jupiter Mines delivered Tshipi production and sales ahead of plan in the September quarter, but weaker manganese prices, higher freight and lower sales volumes sharply reduced earnings. Attributable cash fell to A$52.7 million after dividends and working capital outflows.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Novatti’s AU/NZ quarterly transaction value rose to $1.2 billion, but regulatory disruption to international BPAY payments pushed revenue lower and left Cash EBITDA negative. The company is targeting an early 2027 relaunch while relying on pipeline conversion and product mix improvements to support its next phase of growth.
Claire Turing
Claire Turing
30 Oct 2026
Gratifii says its largest enterprise quarter has put Qantas, Woolworths MarketPlus and other major loyalty programs onto its expanding rewards marketplace. The commercial reach is significant, but the update leaves transaction volumes, margins and cash contribution largely unquantified.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Doctor Care Anywhere’s Q3 revenue rose 16% to £11.3 million as its weight-management business delivered its first full quarter, lifting subscription revenue to 19% of the total. The unaudited update also shows modest consultation growth, higher cash and three new distribution partnerships.
Ada Torres
Ada Torres
30 Oct 2026
Barramundi’s portfolio suffered its worst reported year in decades, with a NZ$42.9 million loss and an adjusted NAV return of -18.2% against a 9.2% benchmark gain. The board is negotiating a new management agreement with Fisher Funds while imposing tighter diversification and risk limits.
Claire Turing
Claire Turing
30 Oct 2026
Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.
Victor Sage
Victor Sage
30 Oct 2026
The Calmer Co. posted record Q1 FY27 revenue of A$2.44 million, powered by a sharp lift in US wholesale orders and continued Coles and Woolworths growth. But with A$953,000 in cash against quarterly operating outflows of A$755,000, the kava company remains dependent on further funding and sustained sales momentum.
Victor Sage
Victor Sage
30 Oct 2026
Murray Cod Australia has posted record quarterly sales and expanded into hundreds of Woolworths and Coles stores, but the growth story still depends on turning distribution gains into recurring cash receipts. Underlying operating cash outflow remained A$4.27 million after excluding a one-off R&D tax incentive, while August fish mortality exposed an operational risk.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive